Brand Name :
Tenex, Intuniv
Synonyms :
guanfacine
Class :
Alpha2-Adrenergic Agonist; Antihypertensive agents
Dosage forms & Strengths:
Adult:
Tablet
1 mg
2 mg
Dosage forms & Strengths:
Tablet
1 mg
2 mg
Extended-release tablet
1 mg
2 mg
guanfacine: they may diminish the serum concentration of CYP3A4 Inducers
guanfacine: they may diminish the serum concentration of CYP3A4 Inducers
guanfacine: they may diminish the serum concentration of CYP3A4 Inducers
guanfacine: they may diminish the serum concentration of CYP3A4 Inducers
guanfacine: they may diminish the serum concentration of CYP3A4 Inducers
may have an increased AV-blocking effect when combined with beta-blockers
may enhance the concentration of serum when combined with guanfacine
may enhance the concentration of serum when combined with guanfacine
may enhance the concentration of serum when combined with guanfacine
may enhance the concentration of serum when combined with guanfacine
may enhance the concentration of serum when combined with guanfacine
may diminish the concentration of serum when combined with guanfacine
may diminish the concentration of serum when combined with guanfacine
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may increase the AV-blocking effect of beta blockers
may increase the AV-blocking effect of beta blockers
They may increase the vasopressor effect when combined with Alpha-/Beta-Agonists
They may increase the vasopressor effect when combined with Alpha-/Beta-Agonists
They may increase the vasopressor effect when combined with Alpha-/Beta-Agonists
They may increase the vasopressor effect when combined with Alpha-/Beta-Agonists
It may increase the vasoconstricting effect when combined with Alpha-/Beta-Agonists
It may increase the hypertensive effect when combined with Alpha-/Beta-Agonists
It may decrease the diagnostic effect when combined with Alpha-/Beta-Agonists
may decrease the antihypertensive effect when combined with alpha2-agonists
may increase the vasoconstricting effect of Ergot Derivatives
CYP3A strong enhancers of the small intestine may reduce the bioavailability of guanfacine
may increase the hypertensive effect
It may increase the hypertensive effect when combined with Alpha-/Beta-Agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
may increase the av-blocking effect of beta-blockers
may increase the av-blocking effect of beta-blockers
may increase the av-blocking effect of beta-blockers
may increase the av-blocking effect of beta-blockers
may increase the av-blocking effect of beta-blockers
may enhance the AV-blocking effect of beta-blockers
may enhance the AV-blocking effect of beta-blockers
may enhance the AV-blocking effect of beta-blockers
may enhance the AV-blocking effect of beta-blockers
may enhance the AV-blocking effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the AV-blocking effect
may increase the AV-blocking effect
may increase the AV-blocking effect
may increase the AV-blocking effect
may increase the AV-blocking effect
it may diminish the excretion rate when combined with permethrin, resulting in an enhanced serum level
fedratinib increases the effect of guanfacine by altering the intestinal/ hepatic CYP3A4 enzyme metabolism
may decrease the therapeutic effect when combined with Alpha2-Agonists
may decrease the therapeutic effect when combined with Alpha2-Agonists
may decrease the therapeutic effect when combined with Alpha2-Agonists
may decrease the therapeutic effect when combined with Alpha2-Agonists
may decrease the therapeutic effect when combined with Alpha2-Agonists
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
It may increase the hypertensive effect when combined with Alpha-/Beta-Agonists
It may decrease the vasoconstricting effect when combined with Alpha-/Beta-Agonists
It may increase the hypertensive effect when combined with Alpha-/Beta-Agonists
It may decrease the therapeutic effect when combined with Alpha-/Beta-Agonists
>10%:
Xerostomia
Somnolence
Headache
Dizziness
Constipation
Fatigue
Abdominal pain
1-10%:
Hypotension
Asthenia
Impotence
Lethargy
Dizziness
Irritability
Nausea
Decreased appetite
Weakness
Insomnia
Bradycardia
Palpitations
Confusion
Depression
Dyspnea
Alopecia
Dermatitis
Diaphoresis
Pruritus
Dyspepsia
Dysphagia
Hypokinesia
Leg cramps
Frequency undefined:
Rash
Exfoliation
Arthralgia
Myalgia
Orthostatic hypotension
Guanfacine is contraindicated in patients hypersensitive to the active ingredient.
Pregnancy consideration:
Guanfacine is not identified with any drug-related side effects in pregnant women.
Breastfeeding warnings:
No data is available regarding the excretion of the drug in breast milk.
Pregnancy category:
Patient information leaflet
Generic Name: guanfacine
Pronounced: gu-aan-fa-cin
Why do we use guanfacine?
Guanfacine is an alpha2 adrenergic agonist. It is used to treat hypertension and ADHD in children.